Tecfidera generic
Tecfidera is an anti-inflammatory drug owned by Biogen Inc. The active ingredient in Tecfidera is dimethyl fumarate and it comes in the form of a delayed-release oral capsule. The drug first got its market authorization on 27th March, 2013. Tecfidera holds a total of 9 patents, none of which have expired yet.
When will Tecfidera generic be available?
As of now, all Tecfidera patents are still valid. The last Tecfidera patent is set to expire on 16th November, 2035. Following this, it can be anticipated that the Tecfidera generic version will be available in the market.
Tecfidera uses
Tecfidera is mainly used for treating relapsing forms of multiple sclerosis both before and after the administration of an inactive vaccine. Its active ingredient, dimethyl fumarate, can effectively manage the symptoms of this disease and slow its progression.
Tecfidera patent expiration
Tecfidera holds 9 active patents. These patents are mainly focused on methods of treating multiple sclerosis and the effective use of Dimethyl Fumarate in vaccination regimens. The last one will expire on 16th November, 2035, after which the Tecfidera generics could be made available. Below are the details of the patents: